Welcome to our dedicated page for Steris Plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris Plc stock.
Steris Plc (STE) is a global leader in medical sterilization and infection prevention solutions, serving healthcare, pharmaceutical, and life sciences industries. This news hub provides investors and professionals with timely updates on corporate developments shaping the critical field of healthcare safety.
Access consolidated Steris news including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our verified updates ensure you stay informed about developments impacting infection control technologies and medical equipment sterilization services.
Key content focuses on financial performance updates, FDA clearances for sterilization systems, contract service expansions, and R&D breakthroughs in decontamination science. All materials are sourced directly from company filings and authorized communications.
Bookmark this page for streamlined access to Steris' official announcements. Check regularly for updates on operational developments affecting healthcare providers and medical device manufacturers worldwide.
STERIS plc (NYSE: STE) will hold a conference call at 9:00 a.m. ET on May 11, 2023, to discuss its fiscal 2023 fourth quarter and full year financial results. The financial results press release will be issued after market close on May 10, 2023. Investors can join the call live at steris-ir.com or by phone. A replay will be available shortly after the call. STERIS is a global leader in providing products and services that enhance patient care, focusing on infection prevention. The company urges checking their website for further updates.
STERIS plc (NYSE: STE) reported a 1% increase in revenue to $1.22 billion for fiscal Q3 2023, compared to $1.21 billion in the previous year. Constant currency organic revenue grew 7%. Earnings per share were $1.24 as reported, with adjusted EPS at $2.02. The company experiences challenges in supply chain and a slower growth in bioprocessing, impacting overall performance. STERIS updated its fiscal 2023 outlook, now expecting 6% revenue growth (previously 8%) and adjusted EPS guidance of $8.00 to $8.10.
STERIS plc (NYSE: STE) announced a quarterly interim dividend of $0.47 per share, payable on March 23, 2023, to shareholders of record as of February 24, 2023. STERIS is recognized as a leading global provider focusing on products and services that enhance patient care and infection prevention. This dividend demonstrates the company’s commitment to returning value to shareholders while reinforcing its role in creating a healthier and safer world through innovative solutions in healthcare and life sciences.
STERIS plc (NYSE: STE) will host a conference call to discuss its fiscal 2023 third quarter financial results on February 9, 2023, at 10:00 a.m. ET. The call will be accessible via the STERIS investor relations website or by phone. A detailed press release regarding the financial results will be issued after the U.S. market closes on February 8, 2023. For those unable to attend, a replay will be available starting at noon on February 9. STERIS is recognized for its infection prevention products and services aimed at supporting patient care.
STERIS plc (NYSE: STE) reported its fiscal 2023 second quarter results, showing revenue was flat at $1.2 billion year-over-year, with a 7% increase in constant currency organic revenue. The company incurred a net loss of $315.3 million, or ($3.15) per share, due to a $490.6 million impairment charge related to its Dental segment. Adjusted earnings per diluted share remained steady at $1.99. The company anticipates foreign currency headwinds affecting revenue growth, now expected to be 8%, down from 9%. Free cash flow projections decreased to $600 million from $675 million.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
